Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466425 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
- 20
- Study locations
NCT02466425 is a Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD) that has completed, run by Shire. The registered enrollment target is 264 participants, above the 130-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT02466425, a Phase 3 study of Attention Deficit Hyperactivity Disorder (ADHD), has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years). The primary objective of this study is to evaluate the efficacy of SHP465 administered as a daily morning dose compared to placebo in the treatment of children and adolescents (6-17 years of age inclusive) diagnosed with ADHD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SHP465
Study Locations (20)
Florida
- Florida Clinical Research Center, Llc - Bradenton
- Sarkis Clinical Trials - Gainesville
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Medical Research Group of Central Florida - Orange City
- Clinical Neuroscience Solutions, Inc. - Orlando
- Miami Research Associates, Llc - South Miami
- Janus Center For Psychiatric Research - West Palm Beach
California
- Nrc Research Institute - Orange
- Pcsd Feighner Research - San Diego
- Encompass Clinical Research - Spring Valley
- Elite Clinical Trials, Inc - Wildomar
Illinois
- Capstone Clinical Research - Libertyville
- Baber Research Group Inc - Naperville
Alabama
- Harmonex Neuroscience Research - Dothan
Colorado
- McB Clinical Research Centers - Colorado Springs
Georgia
- Northwest Behavioral Research Center - Marietta
Kansas
- Psychiatric Associates - Overland Park
Louisiana
- Louisiana Research Associates, Inc - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2015-06-18 |
| Est. Completion | 2016-02-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02466425
The ClinicalTrials.gov registry entry for NCT02466425 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 130-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (103% higher). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder (ADHD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02466425 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02466425 about?
NCT02466425 is a clinical study titled "Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)". The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years). The primary objective of this study is to evaluate the efficacy of SHP465 administered as a daily morning dose compared to placebo in the treatment of children ...
What is the current status of trial NCT02466425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2015-06-18. Estimated completion is 2016-02-16.
What conditions does trial NCT02466425 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder (ADHD).
What interventions are being tested in trial NCT02466425?
The interventions under investigation include: Placebo (DRUG), SHP465 (DRUG).
Who is sponsoring clinical trial NCT02466425?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02466425 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder (ADHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
COMPLETED · Phase 3
-
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
PRC-063 in an ADULT Workplace Environment
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
COMPLETED · Phase 3
-
Improving ADHD Teen Driving - Virtual Reality
RECRUITING · NA
-
Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.